Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.52 |
| ▸ | MEN1 | O00255 | 8/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379733 | 0.79 | KCNK3 (0.50) | RAB9ANPC1KMT2AKCNK3KCNK9 | |
| SCHEMBL2380329 | 0.76 | NPC1 (0.64) | RAB9ANPC1SMN1; SMN2TP53KMT2A | |
| SCHEMBL5991688 | 0.72 | RAB9A (0.80) | RAB9ANPC1SMN1; SMN2TP53KMT2A | |
| SCHEMBL20353537 | 0.72 | ALDH1A1 (0.65) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL15434968 | 0.72 | LMNA (0.74) | RAB9ANPC1SMN1; SMN2TP53KMT2A | |
| SCHEMBL4056753 | 0.71 | CA1 (0.51) | SMN1; SMN2TDP1LMNA | |
| SCHEMBL28148837 | 0.71 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2TP53KMT2A | |
| SCHEMBL833815 | 0.71 | SMN1; SMN2 (0.65) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL23011772 | 0.70 | KCNK3 (0.82) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL31073631 | 0.70 | KMT2A (0.65) | RAB9ANPC1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017601-B2 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1896461-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | Amgen Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | AMGEN INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2007005668-A2 | BIS-ARYL KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF INFLAMMATION, ANGIOGENESIS AND CANCER | AMGEN INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054903-A1 | Bis-aryl kinase inhibitors and method | HGF, MET, BLK | RAB9A 1962/4885NPC1 1163/4885SMN1; SMN2 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.